Back to results
US 9,914,922 B2Granted
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
AssigneeIonis Pharmaceuticals, Inc.
InventorsSusan M. Freier, Eric E. Swayze
Life of this patent
Estimating the term…
Abstract
The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
Claims12
A compound comprising:
- a modified oligonucleotide consisting of 17 to 20 linked nucleosides, wherein the modified oligonucleotide has a motif selected from e-e-e-k-(D)9-k-e-e-e, e-e-e-k-k-(D)8-e-e-e-e, e-k-e-k-(D)9-e-e-e-e, e-k-e-k-d-k-(D)7-e-e-e-e, k-d-k-d-k-(D)10-e-e-e-e-e, k-d-k-d-k-(D)8-e-e-e-e-e, and k-d-k-d-k-(D)8-e-e-e-e;
- and
- wherein each “k” is a bicyclic nucleoside, each “e” is a 2′-substituted nucleoside, each “d” is a 2′-deoxynucleoside, and each “D” is a 2′-deoxynucleoside;
- and
- wherein each 2′ -substitutent is selected from 2′-OMe, 2′-O-methoxyethyl, and 2′-F;
- and
- wherein the nucleobase sequence of the modified oligonucleotide is complementary to the nucleobase sequence of a target nucleic acid.
4 more elements
Dependencies are inferred from the claim text.